Almost all patients survive stage Ia malignant melanoma, and the suvivorship for stage I overall is more than 90%.
Patients with metastatic melanoma who do not respond well to other therapies may be candidates for treatment with aldesleukin.
Some patients, such as those with IIb or stage III melanoma, are at high risk for the development of recurrence after treatment.
Radiation therapy is typically used for malignant melanoma patients in later stages of the disease (stage III or IV). It may be used to shrink tumors, relieve symptoms, or treat specific areas of metastasis.
A positive family history of one or two first-degree relatives having had melanoma substantially increases the risk on a genetic basis. A family tendency is observed in 8% to 12% of patients.
Malignant melanoma also affects non-Caucasians--though sun exposure probably does not play a role--at a rate of 10% that of Caucasians.
For those with familial tendencies for malignant melanoma, genetic counseling may be appropriate. Psychological counseling may be appropriate for anyone having trouble coping with a potentially fatal disease.
The key to successful treatment is early diagnosis. Patients identified with localized, thin, small lesions (typified by superficial spreading subtype) nearly always survive.
In 2003 a group of Swedish researchers reported that 63 out of a group of 71 melanoma patients, or 89% of the group, had mutations in either the NRAS or the BRAF gene.
For stage IV patients, or those that are treated and then develop recurrence at distant sites, chemotherapy or immunotherapy is planned.
Though it does not occur in all patients (5% to 20%, depending on the extremity and extent of the dissection), it can be a disabling symptom.
It is important to get treatment for malignant melanoma. Without treatment, the cancer will go deeper into the skin and spread throughout the body, eventually leading to death.